Cantor Fitzgerald Downgrades Apellis Pharmaceuticals (APLS) to Neutral

April 1, 2026 2:52 AM

Cantor Fitzgerald analyst Steven Seedhouse downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Overweight to Neutral.The analyst comments: "We are downgrading APLS ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found